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1. Introduction 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis 
(MS). MS is also named encephalomyelitis disseminata (ED). EAE has been also called 
experimental allergic encephalomyelitis, but the word `allergic` is more and more replaced 
by the word `autoimmune`. This has to do with the deeper understanding of the disease 
biology that has been gathered over the last years. MS is a chronic autoimmune disease of 
the central nervous system (CNS) that leads to inflammation, demyelination and axonal 
loss. The CNS lesions cause neurological deficits.  
In the beginning the disease course of MS is in most cases relapsing-remitting but changes 
after several years into a secondary chronic progressive disease course (Table 1). More 
rarely, there are also primary progressive disease courses. The diagnosis of MS is often 
preceded by a single demyelinating event for example the appearance of Optic Neuritis 
(ON). There are indications that MS is caused by the activation of autoreactive CNS-specific 
T cells and possibly antibodies that lead to subsequent activation of additional immune 
cascades and lesion formation (Fig. 1). The relapsing phase of MS is thought to be 
predominately mediated by the adaptive phase of the immune response, while progressive 
forms are more driven by innate immune mechanisms (Bhat and Steinman, 2009; Weiner, 
2009). 
The EAE models that are used in the laboratory for assessment of immunological, 
neurobiological and therapeutic studies are all induced models or genetically modified 
models. There is no naturally occurring spontaneous EAE model that is accepted as a 
valuable laboratory model for MS. EAE can be induced in various animal strains and 
species. Most used species are mice and rats. The reason for this is the size, the availability 
of inbred strains and the possibility for genetic modification as well as the immense number 
of tools to characterize rodents. In addition  certain monkey species like marmosets are used 
for specific questions that cannot be easily assessed in rodents (Hart et al., 2011).  
What has become clear over the last years is the fact that EAE is no perfect model for all 
aspects of MS. Rather various different models represent facets of MS. Some models are 
more suited for immunological analyses and this can be further divided into adaptive and 
innate immunity related aspects as well as cellular aspects, like the analysis of influences of 
T and B cells on disease precipitation and maintenance. There are models that are more 
suited for analysis of certain neurobiological aspects of the disease, like axonal and neuronal 
pathology and detailed lesion characterization. 
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Course         Characteristics 
Estimated 
Prevalence 
Relapsing MS (RR-MS, rSP-MS, PR-MS) 
RR-MS 
(Relapsing-remitting 
MS) 
 Presence of relapses and 
remissions 
 Disability due to residual 
symptoms 
22 %  
rSP-MS 
(SP-MS with 
superimposed relapses) 
 Presence of relapses 
 Progressive form, steadily 
increasing disability 
3.5 %  
PR-MS 
(Progressive relapsing 
MS) 
 Presence of relapses 
 Progressive from onset, 
steadily increasing disability 
1.5 %  
Progressive MS without relapses (nrSP-MS, PP-MS) 
nrSP-MS  
(SP-MS without 
superimposed relapses) 
 No relapses 
 Progressive form, steadily 
increasing disability 
 
60 %  
PP-MS  
(Primary progressive 
MS) 
 No relapses 
 Progressive from onset, 
steadily increasing disability 
13 %  
Table 1. Different disease courses of MS. Relapsing disease courses of MS are mainly driven 
by the adaptive immune response (T and B cells) while progressive disease is thought to be 
predominantly mediated by innate immunity. In most cases, relapsing disease changes over 
the course of MS to secondary progressive disease. As outlined in Table 10, specific EAE 
models can be used to mimic the aspects of different types and variants (Devic´s, ADEM) of 
MS. 
MS variants can be modeled in rodents. For example Acute Disseminated Encephalomyelitis 
(ADEM), an acute inflammatory reactive disease of the CNS, and Neuromyelitis Optica 
(Devic`s disease) can be modeled in certain rodent species as outlined further below. The 
researcher who wants to use EAE as a model should be aware of all the various types of 
EAE and should be careful in selecting the correct species, strain and immunization 
protocol, since depending on these factors, the outcome and interpretability of the research 
will differ. The selection of the specific model might differ strongly between an 
immunologist who wants to assess basic principles of organ specific autoimmunity in 
contrast to the MS researcher who wants to analyze specific disease aspects or a new 
therapeutic approach in preclinical pharmacology studies. 
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Fig. 1. Possible cascade for induction of MS. So far it is not clear what induces MS. Trigger 
factors are possibly infections, adjuvants or the endogenous presentation of self antigens 
(Fissolo et al., 2009). On the ground of a genetic predisposition with the possible cofactors 
vitamin D and sunlight exposure the disease is induced and autoimmunity is maintained by 
aberrant immune cascades that will finally lead to myelin/oligodendrocyte pathology as 
well as axonal and neuronal loss.  
2. EAE models 
Nowadays widely used EAE models in rats are the monophasic EAE in LEW rats that is 
induced with Myelin Basic Protein (MBP) or MBP peptides and Complete Freund´s 
Adjuvant (CFA) (Table 2). CFA consists of the mineral oil Incomplete Freund´s Adjuvant 
(IFA) mixed with heat killed extract from Mycobacterium Tuberculosis (MT). As prototype 
chronic EAE model in rats, EAE induced in DA rats with whole myelin extract in IFA or the 
extracellular domain of Myelin Oligodendrocyte Glycoprotein (MOG) in CFA or IFA have 
high value for studies regarding MS disease biology and therapeutic interventions. Whole 
myelin extract for this model is typically obtained from autologous spinal cord of DA rats. 
Interestingly DA rats develop EAE with the myelin extract/MOG with IFA alone.   
In mice the most used model is the chronic model in C57BL/6 mice induced with the 
extracellular domain of MOG or MOG peptide 35-55 and CFA as well as Pertussis Toxin 
(PT) as adjuvant (Table 2). Other valuable models are the chronic relapsing EAE model 
induced with PLP or PLP peptide 139-151 in SJL mice with CFA and PT as ajduvants, the 
chronic relapsing EAE model induced in Biozzi mice with the extracellular domain of MOG 
or MOG peptide 92-106 in CFA and PT, the chronic progressive EAE induced in 
autoimmunity prone NOD mice with MOG peptide 35-55 and the monophasic EAE induced 
with MBP peptide Ac1-11 (or MBP peptide Ac1-9) with CFA and PT in PL/J mice.  
There are relapsing progressive EAE models that can be induced with Theiler`s Murine 
Encephalitis Virus (TMEV) (Table 2). Interestingly in the TMEV model, antigen spreading to 
the classical myelin antigens can be observed during the disease course. Genetically  
Trigger factors
Genetic
Predisposition
Possible cofactors:
Vitamin D levels
Sunlight exposureInfection?
Adjuvants?
Endogenous
presentation of
self antigen?
Induction of disease
Autoimmunity
T and B cells recognize
myelin fragments, i.e.
Proteolipid protein
Myelin-basic protein
Myelin-oligodendrocyte glycoprotein
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Species Strain Induction Disease type Reference 
Rat LEW MBP or MBP 68-88 
peptide in CFA 
Acute monophasic (Mannie et al., 1985; 
McFarlin et al., 1975)  
Rat DA Spinal cord in IFA 
or MOG 1-125 in 
CFA or IFA 
Relapsing/progressive (Lorentzen et al., 
1995; Weissert et al., 
1998b) 
Mouse PL/J MBP, MBP Ac1-11 
(or Ac1-9)  in CFA + 
PT 
Acute monophasic (Zamvil et al., 1986) 
Mouse SJL PLP protein or PLP 
139-151 peptide in 
CFA + PT 
Chronic relapsing (Kuchroo et al., 1991)  
Mouse C57BL/6 MOG protein or 
MOG 35-55 peptide 
in CFA + PT 
Progressive or acute (Mendel et al., 1995; 
Oliver et al., 2003)  
Mouse Biozzi MOG protein or 
MOG 92-106 
peptide in CFA + 
PT  
Chronic relapsing (Baker et al., 1990)  
Mouse NOD MOG 35-55 peptide 
in CFA + PT 
Chronic progressive (Maron et al., 1999) 
Mouse SJL Theiler’s murine 
encephalitis virus 
Relapsing progressive (Olson et al., 2001)  
Mouse B10.PL-
H2u 
TCRMBP transgenic  Spontaneous acute (Goverman et al., 
1993)  
Mouse C57BL/6 TCRMOG transgenic Optic neuritis (Bettelli et al., 2003) 
Mouse C57BL/6 TCRMOGXIgHMOG 
transgenic  
Spontaneous Optico-
spinal disease 
(Bettelli et al., 2006; 
Krishnamoorthy et 
al., 2006) 
 
Table 2. Presently most used EAE models for laboratory research. The list only provides a 
part of all available EAE models. CFA = Complete Freund`s Adjuvant; IFA = Incomplete 
Freund`s Adjuvant; PT = Pertussis Toxin. 
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modified models include the spontaneous EAE in C57BL/6 mice that have a T Cell Receptor 
(TCR) specific for MBP peptide 1-9. Another genetically modified C57BL/6 mouse with a 
MOG specific TCR and a MOG specific B Cell Receptor (BCR) or surface Immunoglobulin 
(sIg) develop spontaneous EAE and can be very useful for assessment of specific scientific 
questions. 
There are rodent EAE models that can be induced by passive transfer of T cells. These 
models are not subject of this chapter and are therefore not outlined in detail. T cell transfer 
models have been very suitable for immunological investigations mainly in regard to the 
dissection of the role of T cells in organ-specific autoimmunity (Krishnamoorthy and 
Wekerle, 2009). 
3. Establishment of Myelin-Oligodendrocyte-Glycoprotein (MOG)- induced 
EAE in rats 
The rat is a good species to perform EAE studies due to its larger size as compared to mice, 
the availability of many well characterized inbred strains, its strong standing for 
pharmacological studies and its great value for behavioral outreads. In addition novel ways 
for genetic modification are increasingly becoming available. The rat Major 
Histocompatibility Complex (MHC) is called RT1. The classical MHC I molecule is called 
RT1.A, the MHC II molecules are named RT1.B and RT1.D that are equivalent to HLA-DQ 
(RT1.B) and HLA-DR (RT1.D) (Fig. 2, Table 3).  
 
Fig. 2. Organization of MHC in different species (human [HLA], rat [RT1], mice [H2]). There 
are considerable differences in the organization between HLA, H2 and RT1 (Günther and 
Walter, 2001). 
EAE induced with whole myelin extracts or MBP in LEW (RT1l) rats has been used over 
many years (Table 2). This model is monophasic and was the prototype EAE model in the 
past. Much understanding regarding MS pathogenesis, immunology and neurobiology has 
been obtained over the years. The model is very useful to study basic immunological 
principles regarding T cell migration to the CNS and T cell related immunity of MS. This 
Ke3  K      P                 A    E     C4           Hsp70           TNF      D     L            Q           T           M  MOG
H-2
(mouse)
Class I            II                             III                                      I
Ke3    A      H               B      D    C4           Hsp70           TNF                     C M  MOG
RT1
(rat)
Class I            II                             III                                      I
Ke3      DP                  DQ   DR   C4     Hsp70           TNF                 B        C            A MOG
HLA
(human)
Class II                                III             I
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model is often used for pharmacological investigations in EAE. Beside with whole myelin 
extracts the model can be induced with MBP protein (various isoforms) or peptides from the 
main encephalitogenic regions MBP 89-101 and MBP 68-88. Interestingly MBP peptide 89-
101 binds to RT1.Dl (HLA-DR-like), while MBP 68-88 binds to RT1.Bl (HLA-DQ-like) (de 
Graaf et al., 1999; Weissert et al., 1998a). There are species dependent effects of MBP on 
disease development. We could demonstrate that the MBP peptide 63-88 derived from 
Guinea Pig (GP) as compared to the MBP peptide 63-88 derived from rat is much more 
encephalitogenic. Immunization with MBPGP63-88 results in the agglomeration of T cells in 
the CNS that express up to 30% the TCRBV chain 8.2 (TCRBV8S2), while after immunization 
with MBPRAT63-88 there is not such a strong overusage of such T cells in the CNS (Weissert 
et al., 1998a). Based on this fact it can also be understood that therapeutic manipulation in 
the context of immunization with MBPGP63-88 is more demanding as compared to 
MBPRAT63-88. We equally demonstrated that MBP derived peptides of different species can 
act as superagonists, agonists or antagonists depending on the expressed MHC II haplotype 
(de Graaf et al., 2005).  
 
Strain*   Class I  Class II  Class III Class I 
 Haplotyp RT1.A RT1.B RT1.D  RT1.C 
DA av1 a a a av1 av1 
COP av1 a a a av1 av1 
ACI av1 a a a av1 av1 
PVG-RT1a (DA) av1 a a a av1 av1 
LEW.1AV1 (DA) av1 a a a av1 av1 
LEW l l l l l l 
LEW.1N (BN) n n n n n n 
LEW.1A (AVN) a a a a a a 
LEW.1W (WP) u u u u u u 
LEW.1AR1 r2 a u u u u 
LEW.1AR2 r3 a a a u u 
LEW.1WR1 r4 u u u a a 
LEW.1WR2 r6 u a a a a 
BN n n n n n n 
Table 3. RT1 haplotypes of inbred rat strains (Weissert et al., 1998b). RT1.B is the rat 
equivalent to HLA-DQ and RT1.D to HLA-DR. *Donor strain in brackets 
It was demonstrated that as compared to LEW rats, DA rats develop in a much higher 
incidence chronic disease after immunization with autologous whole spinal cord 
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homogenates (Lorentzen et al., 1995). In DA rats immunization of autologous whole spinal 
cord in IFA is sufficient to induce this type of chronic disease. Interestingly it was found that 
DA rats develop antibodies against the MOG extracellular domain MOG 1-125. Based on 
this fact we were interested to assess the encephalitogenic potential of MOG 1-125 in DA 
rats and other inbred rat strains. We found that immunization with MOG 1-125 in CFA 
resulted in relapsing-remitting disease (Weissert et al., 1998b). Also the immunization of 
MOG 1-125 in IFA causes to this type of disease. Interestingly for the first time it was 
observed in rodents that the rats developed ON in addition to classical EAE symptoms 
(Storch et al., 1998). In addition, specific immunization protocols allowed the selective 
induction of ON. ON is a typical aspect of MS. The CNS lesions in this model have much 
greater similarity to MS as compared to the lesions in LEW rats immunized with MBP or 
MBP peptides. Widespread demyelination was present and the analysis of lesions resulted 
in the important insight that beside T cells also antibodies contribute to lesion formation in 
this model. In contrast to MBP, MOG is expressed on the exterior part of the myelin sheath 
and the Ig-like domain can be recognized by antibodies. Binding of antibodies to MOG can 
activate a number of immune mechanisms like the activation of macrophages and 
complement deposition that can result in increased tissue damage as compared to purely T 
cell mediated pathology. 
Based on the findings in DA rats and immunization with MOG we were wondering about 
the encephalitogenic potential in rat strains with different MHC haplotypes. This question 
appeared important to us, since it has been demonstrated for a long time that the MHC II 
region has a strong genetic influence on MS (Sawcer et al., 2011). Therefore we used a large 
number of inbred congenic LEW rat strains that express a wide variety of MHC haplotypes. 
In addition we used various inbred rat strains (Table 3) (Weissert et al., 1998b).  
We observed that certain rat strains developed relapsing-remitting or chronic progressive 
disease, others hyperacute progressive disease, some slow progressive disease with 
predominance of cortical pathology and others were protected (Table 4). Also the selection 
of the adjuvant had additional effects. While LEW.1N (RT1n) immunized with MOG 1-125 in 
CFA developed hyperacute progressive disease that often lead to death due to pontine 
lesions, immunization with MOG 1-125 in IFA resulted in chronic progressive disease with 
axonal pathology that has great similarity to MS (Kornek et al., 2000).  
We also observed that LEW (RT1l) rats immunized with MOG 1-125 did not develop EAE 
(Weissert et al., 1998b). This is in contrast to immunization protocols with MBP or MBP 
peptides which lead to EAE as outlined above (Weissert et al., 1998a). Based on the fact that 
LEW.1AV1 rats that carry the RT1av1 haplotype derived from the DA rat develop EAE after 
immunization with MOG 1-125, we concluded that the MHC haplotype is operating in the 
context of the myelin antigen used for immunization (Weissert et al., 1998b). This was 
further supported by the observation that LEW.1N (RT1n) rats and BN (RT1n) rats do not 
develop disease after immunization with MBP, but strong disease after immunization with 
MOG 1-125. This finding appears of some importance since it might explain why MHC 
haplotypes might differ as susceptibility loci in different parts of the world: depending on 
the environmental challenges that differ in different regions of the world, the subsequent 
induction of immunity against certain myelin components might differ. For example in 
Western Europe and North America the main susceptibility HLA allele is HLA-DR2b, while 
in Sardinia it is HLA-DR4 (Marrosu et al., 1997).  
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We described rat strains that carried MHC haplotypes that allow disease development after 
immunization with MOG 1-125 but which were protected by non-MHC genomes. We 
defined that ACI rats as well as MHC congenic PVG-RT1av1 that both carry the RT1av1 
haplotpye were protected from EAE (Weissert et al., 1998b). Subsequent large genetic 
screens allowed dissection of some of the susceptibility genes (Swanberg et al., 2005). 
 
Species Strain Induction Disease type Reference 
Rat LEW.1A MOG1-125 in CFA Chronic progressive (Weissert et al., 1998b) 
Rat LEW.1AV1 MOG1-125 in CFA Relapsing-remitting (Weissert et al., 1998b) 
Rat LEW.1AV1 MOG1-125 in IFA Relapsing-remitting (Kornek et al., 2000) 
Rat LEW.1N MOG1-125 in CFA Hyperacute 
progressive 
(Weissert et al., 1998b) 
Rat LEW.1N MOG1-125 in IFA Chronic progressive (Kornek et al., 2000) 
Rat LEW.1W MOG1-125 in CFA Slow progressive (Weissert et al., 1998b) 
Rat LEW.1AR1 MOG1-125 in CFA Slow progressive, 
cortical pathology 
(Storch et al., 2006; 
Weissert et al., 1998b) 
Rat DA MOG1-125 in CFA Relapsing-remitting, 
optic neuritis 
(Storch et al., 1998; 
Weissert et al., 1998b) 
Rat BN MOG1-125 in CFA Neuromyelitis optica (Meyer et al., 2001; 
Weissert et al., 1998b)  
Table 4. EAE models induced with MOG 1-125 in rats. Different disease courses and types of 
CNS pathology can be induced that are dependent on the MHC haplotype. 
We found one LEW rat strain with a specific MHC haplotype that predominantly develops 
cortical lesions, LEW.1AR1 (RT1r2) rats (Storch et al., 2006; Weissert et al., 1998b). Recently 
cortical lesions have been acknowledged as a primary cause of disability in MS. Cortical 
lesions can be also induced in LEW rats with a subencephalitogenic immunization with 
myelin components and subsequent local intrathecal application of Tumor Necrosis Factor 
alpha (TNF) (Merkler et al., 2006). Marmosets immunized with MOG 1-125 can develop 
cortical lesions as well (Pomeroy et al., 2005). By now it has also been observed that certain 
mouse strains can develop cortical pathology (Mangiardi et al., 2011). In our observation 
LEW.1AR1 rats immunized with MOG 1-125 in CFA represent the most suitable and 
reproducible model for cortical pathology of MS and possible therapeutic manipulation. 
In a next step we were interested to define the encephalitogenic stretches within the 
extracellular domain of MOG 1-125 (Tables 5, 6). In order to do this we used 18 amino acid 
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long overlapping peptides of the MOG 1-125 rat sequence (Weissert et al., 2001). We 
performed this study in many different inbred and inbred MHC congenic rat strains. 
Interestingly we found that only MOG 91-108 in CFA induced disease in rat strains with 
the RT1av1 or RT1n haplotype. Rat strains with the RT1av1 haplotype are DA rats and 
LEW.1AV1 rats and rats with the RT1n haplotype LEW.1N and BN rats. We found that 
MOG 91-108 bound well to purified RT1.Ba molecules and to RT1.Dn molecules. 
Immunization with MOG 91-108 induced a T and B cell response. In LEW.1N rats this T 
cell response was difficult to measure and we concluded early that other factors than 
classical Th1 mediated cytokines might be operative contributing to disease precipitation 
(Weissert et al., 2001).  
In most instances the immunodominant peptides did not correspond to the peptides that 
were capable of inducing EAE. We concluded that the immune response to the 
immunodominant peptides might be also a signature of a regulatory T cell response (we 
called it `modulatory).  
 
RT1 RT1.A RT1.B/D RT1.C Strain Disease 
inducing 
peptides 
Peptides that raise 
an immuno-
dominant T cell 
response 
l l l l LEW none MOG 37-54 and 
MOG 43-60 
u 
r4 
r2 
u 
u 
a 
u 
u 
u 
u 
a 
u 
LEW.1W 
LEW.1WR1 
LEW.1AR1 
none None 
a 
r3 
r6 
av1 
av1 
av1 
a 
a 
u 
a 
a 
a 
a 
a 
a 
a 
a 
a 
a 
u 
a 
av1 
av1 
av1 
LEW.1A 
LEW.1AR2 
LEW.1WR2 
LEW.1AV1 
DA 
COP 
MOG 91-
108, MOG 
96-104 
MOG 73-90, MOG 
91-108 
av1 
av1 
a 
a 
a 
a 
av1 
av1 
PVT-RT1av1 
ACI 
none none 
n 
n 
n 
n 
n 
n 
n 
n 
LEW.1N 
BN 
MOG 91-
108, MOG 
98-106 
MOG 19-36 
Table 5. MOG peptides that induce disease and immune responses. Most MOG stretches 
that induce strong immune responses in rats do not induce EAE (Weissert et al., 2001). 
www.intechopen.com
Experimental Autoimmune Encephalomyelitis  
– Models, Disease Biology and Experimental Therapy 12
Species Strain Induction Disease type Reference 
Rat DA MOG91-108 in 
CFA 
Monophasic or 
chronic  
(Weissert et al., 
2001) 
Rat LEW.1AV1 MOG91-108 in 
CFA 
Monophasic or 
chronic  
(Weissert et al., 
2001) 
Rat LEW.1N MOG91-108 in 
CFA 
Monophasic or 
chronic  
(Weissert et al., 
2001) 
Rat LEW.1AV1 MOG96-104 in 
CFA 
Monophasic or 
chronic  
(de Graaf et al., 
2008) 
Rat LEW.1N MOG98-106 in 
CFA 
Monophasic or 
chronic 
(de Graaf et al., 
2008) 
Table 6. EAE models induced with MOG peptides. Based on detailed immunological 
analysis the region MOG 91-108 was defined as the encepathalitogenic region in different rat 
strains. Further dissection allowed the narrowing of the disease inducing MOG stretches to 
nine amino acid long peptides.   
We observed that complement depletion does lead to protection from disease, underscoring 
the influence of antibodies to MOG. Crystallographic studies have indicated that the region 
MOG 91-108 is accessible to antibodies (Breithaupt et al., 2008). In addition, we 
demonstrated by spectroscopic TCR analysis that depending on the expressed RT1 
haplotype, the predominance of certain TCRBV chains was the same in rat strains with 
different non-MHC genomes underscoring the strong influence of the MHC II haplotype on 
TCRBV usage in the MOG model (de Graaf et al., 2008).  
For the rat EAE models, we measured the binding strength of the encephalitogenic peptides 
by comptetitive binding assays (Table 7). We could show that the peptides that induce EAE 
are binding well to the MHC II molecules that present the peptides to T cells (de Graaf et al., 
2008; de Graaf et al., 1999; Weissert et al., 2001; Weissert et al., 1998a). We dissected the 
binding qualities to purified RT1.B and RT1.D molecules and the T and B cell response to 
MOG 91-108 in LEW.1N and LEW.1AV1 rats. We found that the peptides that bound 
strongest, induced EAE. This were the peptides MOG 96-104 in LEW.1AV1 rats binding to 
RT1.Ba and MOG 98-106 in LEW.1N rats binding to RT1.Dn. With increasing shortening of 
the peptides, the evolving disease was partly reduced, indicating that possibly there was a 
reduction in the activated encephalitogenic T cell repertoire (de Graaf et al., 2008).  
That peptides which induce EAE bind strongly to the restricting MHC II molecule is in 
agreement with measured binding strengths in humanized mouse models, but contrasts 
findings in the PL/J mouse in which the encephalitogenic peptide MBP Ac1-9 binds only 
very weakly to the I-Au MHC II molecule. While in the first case the persistence of antigen 
might lead to breaking of tolerance, in the latter case, the escape from tolerance might be of 
primary importance in disease establishment. 
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Haplotype 
(Strain) 
Encephalitogen Restriction IC50 (µM) Reference 
RT1l (LEW) MBPgp72-85 Bl 2,5 (Weissert et al., 1998a)  
MBP 87-99 Dl 0,02 (de Graaf et al., 1999)  
RT1av1 (DA, 
LEW.1AV1) 
MBP 87-99 Ba 0,06 (de Graaf et al., 1999)  
MOG 91-108, MOG 
96-104 
Ba 9,5 (de Graaf et al., 2008; 
Weissert et al., 2001) 
RT1n (BN, 
LEW.1N) 
MOG 91-108, MOG 
98-106 
Dn 0,03 (de Graaf et al., 2008; 
Weissert et al., 2001) 
H-2s (SJL/J) MBP 81-100 I-As 0,36 (Wall et al., 1992) 
PLP 100-119 I-As 1,24 (Greer et al., 1996)  
PLP 139-151 I-As 0,04 (Greer et al., 1996)  
PLP 178-191 I-As 0,74 (Greer et al., 1996)  
H-2u (PL/J) MBP Ac1-9 I-Au > 100 (Fairchild et al., 1993; 
Liu et al., 1995) 
HLA-DR2 
transgenic mice  
MBP 84-102 DRB1*1501 0,004 (Madsen et al., 1999; 
Wucherpfennig et al., 
1994) 
HLA-DR4 
transgenic mice 
MOG 91-108 DRB1*0401 0,3 (Forsthuber et al., 2001) 
Table 7. Binding of EAE inducing peptides to purified MHC molecules. Binding strengths 
were assessed with competitive binding assays and affinity purified MHC II molecules. 
In summary we made a major step in establishing more suitable models to study MS disease 
biology and therapeutic interventions. In addition we were able to obtain a large quantity of 
insight into the immune regulation in the context of genetic factors in a complex 
autoimmune disease. We demonstrated the major influence of MHC II haplotypes on 
disease regulation, but for the first time also of MHC I. Recently also for MS influences of 
MHC I loci on susceptibility could be confirmed (Sawcer et al., 2011).  
4. Ways of EAE induction with either MBP, PLP or MOG and choice of the 
relevant animal model/strain 
Beside the selection of the right species and strain, the selection of the model antigen is of 
great importance for the outcome of the EAE studies. The sequences of the most used 
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stretches of myelin proteins for disease induction used in different species are listed in Table 
8. The peptides should have a high degree of purity and it is advisable to prepare large 
batches that can be used over long term for experimentation. In the case of EAE induction 
with recombinant antigens, also larger scale preparation and usage of identical batches over 
longer time is recommendable, since there is the danger of batch to batch variation that can 
dramatically affect the outcome of experimentation. 
In addition to species, strain and antigen, the adjuvant is of major importance for the success 
of the EAE induction and the outcome of the experimentation (Table 9). While in the rat 
models, the usage of IFA or CFA is sufficient, nearly all mouse models require the addition 
of PT in the immunization protocol and booster immunizations. The preparation of the 
antigen/adjuvant mixture requires much care and the presence of a homogenate emulsion is 
needed for successful immunizations.  
In the past immunizations have often been performed in the foot pads of the rodents. Due to 
obvious ethical reasons, this procedure is not any more applied. In addition this procedure 
results in the swelling of the footpads affecting gait. This type of gait disturbance can blur 
EAE symptoms with the consequence of wrongly reported EAE scores. Nowadays, in rats 
the immunization is done as a single injection in the base of the tail, while in mice multiple 
injections in the flanks are used for the procedure. It is advisable to establish the best suited 
immunization protocol in the laboratory with care, after the selection of the model based on 
scientific rationales has been performed. 
 
 
 
Myelin protein stretch Sequence 
MBPMOUSE Ac1-9 Ac-ASQKRPSQR 
PLPMOUSE 139-151 HSLGKWLGHPDK 
MOGMOUSE 35-55 MEVGWYRSPFSRVVHLYRNGK 
MBPRAT 68-88 HYGSLPQKSQRTQDENPVVHF 
MBPGP68-88 HYGSLPQKSQRSQDENPVVHF 
MBPRAT 89-101 VHFFKNIVTPRTP 
MOGRAT 91-108 SDEGGYTCFFRDHSYQEE 
MOGRAT Ac96-104 Ac-YTCFFRDHS-NH2 
MOGRATAc98-106 Ac-CFFRDHSYQ-NH2 
 
 
Table 8. Sequences of myelin peptides used for EAE induction in mice and rats 
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Species/ 
strain  
Immunogen Primary 
adjuvant 
Secondary 
adjuvant  
Injection 
site 
Reference 
Mouse      
PL/J MBP Ac1-11 CFA PT Flanks (Zamvil et al., 1986) 
SJL PLP 139-151 CFA PT Flanks (Kuchroo et al., 1991) 
Biozzi MOG 1-125 CFA PT Flanks (Baker et al., 1990) 
C57Bl/6 MOG 35-55 CFA PT Flanks (Oliver et al., 2003) 
Rat      
LEW MBP CFA None Tail base (Weissert et al., 2000) 
LEW MBP 68-88 CFA None Tail base (Weissert et al., 1998b) 
LEW  MBP 89-101 CFA None Tail base (Weissert et al., 2000) 
LEW PLP CFA None Tail base (Zhao et al., 1994) 
DA, 
LEW.1AV1, 
BN, 
LEW.1N, 
LEW1.AR1 
MOG 1-125 CFA or 
IFA 
None Tail base (Kornek et al., 2000; 
Storch et al., 2006; 
Weissert et al., 1998b) 
DA, 
LEW.1AV1 
MOG 91-108, 
MOG 96-104 
CFA None Tail base (de Graaf et al., 2008; 
Weissert et al., 2001) 
LEW.1N or 
BN 
MOG 91-108, 
MOG 98-106 
CFA None Tail base (de Graaf et al., 2008; 
Weissert et al., 2001)  
Table 9. Immunization regimen for different EAE models and usage of adjuvants. CFA = 
Complete Freund`s Adjuvant; IFA = Incomplete Freund`s Adjuvant; PT = Pertussis Toxin. 
5. Conclusions 
It is well possible to induce different aspects of MS in rodent EAE models (Table 10). Some 
models are more suited for immunological analysis, while others better serve the 
neuroscience community. None of the models can model all aspects of MS. Based on the 
specific scientific question, the most suitable EAE model for a specific analysis should be 
selected based on the characteristics of the model. The selection of the best suited model will 
result in better results of the overall research project and will improve the interpretability of 
the results.  
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Course of MS Type of EAE Strain Immunization 
Relapsing forms of MS    
RR-MS MOG-EAE DA, LEW.1AV1 MOG 1-125 
rSP-MS MOG-EAE DA MOG 1-125 
PR-MS MOG-EAE LEW.1N MOG 1-125 
Non-relapsing forms of MS    
nrSP-MS MOG-EAE LEW.1A MOG 1-125 
PP-MS MOG-EAE LEW.1W, 
LEW.1WR1 
MOG 1-125 
Specific pathologies or rare 
MS variants 
   
Predominance of cortical 
lesions 
MOG-EAE LEW.1AR1 MOG 1-125 
Devic`s disease MOG-EAE BN MOG 1-125 
ADEM MBP-EAE LEW MBPGP68-88, 
MBPRAT68-88 
Table 10. Best suited rat model to investigate aspects of different MS types and MS variants 
The MOG-EAE model in rats with the availability of various inbred and RT1 congenic 
strains provides a very good and well defined system for assessment of pertinent questions 
regarding MS disease biology and therapeutic interventions. 
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